[Featured Stock] Shinpung Pharmaceutical's Stock Plummets After COVID-19 Treatment Phase 3 Clinical Trial Failure
On the 19th, Shinpoong Pharmaceutical's stock price plunged sharply in early trading.
As of 9:38 a.m. that day, Shinpoong Pharmaceutical's stock was trading at 10,020 KRW, down 26.30% from the previous trading day.
The decline appears to be due to news that 'Piramex,' a malaria treatment developed by Shinpoong Pharmaceutical as a COVID-19 treatment, failed to prove efficacy in Phase 3 clinical trials.
Hot Picks Today
Samsung Electronics Introduces New "Special Performance Bonus" for Semiconductors, Paid Entirely in Company Shares
- "Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- Opening a Bank Account in Korea Is Too Difficult..."Over 150,000 Won in Notarization Fees Just for a Child's Account and Debit Card" [Foreigner K-Finance Status]②
- Jeon Du-hwan with a Starbucks Tumbler, "Donjjul" Proof Shots... Has Starbucks Become a Far-Right Symbol?
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
Shinpoong Pharmaceutical stated that it is currently conducting a detailed analysis of Piramex's efficacy and safety and will decide on future development directions based on the results.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
!["Please Help Us": How Much Do Those Bowing Deeply for Your Vote Really Earn? [Data Pick]](https://cwcontent.asiae.co.kr/asiaresize/307/2026052010120870131_1779239528.png)
